Although BCNU wafers may not provide a beneficial effect on the prognosis in highly invasive phenotype of GBM, the treatment may have potential to improve the survival in a low-invasive phenotype of GBM expressing CD44 at a low level in the tumor periphery of GBM. The gene discussed is CD44; the disease is neoplasm.